Tempest Therapeutics (TPST) AI Stock Analysis

The negative EPS of -6.01 and resulting negative PE ratio indicate that Tempest Therapeutics is currently loss-making with no clear line of sight to profitability based on the provided data. The lack of any positive earnings metric suggests the company is still in a capital-consuming phase typical of early-stage or clinical-stage biotechs.

• Negative EPS of -6.01 implies substantial net losses on a per-share basis, signaling that operations are not yet self-funding.
• PE ratio of -0.17 confirms the absence of positive earnings and limits the usefulness of traditional valuation multiples, pushing investors to focus on pipeline and catalysts rather than fundamentals.
• Without evidence of revenue growth or improving profitability ratios, the financial profile appears high risk and heavily dependent on future clinical or strategic milestones.

At $1.04, the stock is trading significantly below its 200-day moving average of $2.41, indicating a pronounced downtrend and weak longer-term momentum. This technical setup typically reflects negative sentiment and a lack of sustained buying interest.

• Price ($1.04) is far below the 200-day moving average ($2.41), a classic sign of a sustained bearish trend and technical overhead resistance.
• Trading below a major long-term moving average often means prior investors are sitting on losses, which can create selling pressure on any rallies.
• While RSI is not provided, the large discount to the 200-day average suggests the stock has been under persistent pressure, with sentiment skewed toward risk-off rather than accumulation.

The absence of current job openings and relatively modest social media following point to a small-scale operation with limited visible growth investment or commercial build-out. These signals are more consistent with a lean, early-stage biotech than with a company gearing up for rapid expansion or commercialization.

• Zero job openings suggest no active scaling of headcount, which can imply constrained resources, cautious spending, or a lack of near-term growth initiatives.
• Social media presence is limited (391 followers on Twitter/X and 4,753 on LinkedIn), indicating low brand awareness and a relatively narrow investor and stakeholder reach.
• No evidence of strong alternative data momentum (such as rising hiring, engagement, or digital footprint) to offset the weak financial and technical profile.

Taken together, Tempest Therapeutics exhibits a high-risk profile characterized by negative earnings, a stock price well below its 200-day moving average, and muted alternative data signals. Without clear signs of improving fundamentals or strong external momentum, the current setup leans bearish and heavily dependent on future binary catalysts typical of small biotech names.

• Negative earnings and a depressed share price relative to long-term technical levels point to ongoing financial and sentiment headwinds.
• Limited hiring and modest social media reach provide little evidence of near-term operational scaling or expanding investor interest, reinforcing a cautious, bearish stance.